Drug Profile
Sonidegib - Sun Pharmaceutical Industries
Alternative Names: Erismodegib; Erismodegib-phosphate; LDE-225; NVP-LDE-225; Odomzo; Sonidegib-phosphateLatest Information Update: 18 Dec 2023
Price :
$50
*
At a glance
- Originator Novartis
- Developer Academic Medical Center; Celgene Corporation; Groupe Francophone des Myelodysplasies; Massachusetts General Hospital; Mayo Clinic; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Novartis; Sanofi; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Stanford University; Sun Pharmaceutical Industries; University of Alabama at Birmingham; University of Zurich
- Class Antineoplastics; Biphenyl compounds; Morpholines; Phenyl ethers; Pyridines; Small molecules
- Mechanism of Action SMO protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Basal cell cancer
- Phase II Haematological malignancies; Medulloblastoma; Multiple myeloma; Solid tumours
- Phase I/II Myelofibrosis; Pancreatic cancer
- No development reported Breast cancer; Chronic myeloid leukaemia; Graft-versus-host disease; Liver cancer; Myelodysplastic syndromes; Oesophageal cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer
- Discontinued Basal cell nevus syndrome
Most Recent Events
- 20 Oct 2023 Efficacy data from a phase II BOLT trial in Basal cell carcinoma presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 13 Aug 2021 Novartis Pharmaceuticals in collaboration with Mayo Clinic completed a phase II trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (NCT02086552)
- 04 Jun 2021 Efficacy and adverse events data from a phase II trial in Pancreatic cancer presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)